SecBot SecBot

VTVT drug pipeline

vTv Therapeutics Inc. · 2 rated drugs
$17.69
−10.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±11.0%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.

cadisegliatin Updated Nov 8

What to watch

The next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.

Bull case
  • Cadisegliatin has FDA Breakthrough Therapy designation (May 2026) and Orphan Drug Designation (October 2026), signaling regulatory interest and potential for accelerated development and priority review.
  • Phase 2 SimpliciT-1 data showed HbA1c improvement and fewer severe hypoglycemia events, a compelling profile for an oral adjunctive therapy in T1D where no oral adjunctive options currently exist.
  • Analyst consensus is strongly bullish: 12 analysts rate it Buy/Strong Buy with a mean price target of $56, implying 166% upside from the current ~$21 stock price near its 52-week low.
Bear case
  • Phase 3 CATT1 topline results are not expected until mid 2027, leaving a long period with no binary catalyst during which the stock could drift or face dilution.
  • The company reported a Q3 2026 net loss of $11.62 million, and with no approved products generating revenue, vTv will likely need to raise capital, causing shareholder dilution.
  • The drug was placed on clinical hold by the FDA in July 2024 (lifted March 2025), indicating regulatory risk and potential for future holds if safety signals emerge.
● neutral
Impact
PhasePreclinical
Time to marketYears away from potential commercialization if development proceeds. The drug is still preclinical with no IND filed; typical timelines from preclinical to approval in sickle cell disease are 5-10 years, assuming successful clinical development.

HPPD Updated Nov 8

What to watch

HPPD has no hard dated catalyst in the next ~12 months; the next major binary event for vTv Therapeutics is the Phase 3 CATT1 topline readout for cadisegliatin expected mid-2027. Any partnership deal for HPPD could provide a non-dilutive cash infusion and serve as a positive catalyst, but is not guaranteed. Watch for IND filing announcements or partnership news as the next potential HPPD-specific catalysts.

Bull case
  • First-in-class oral Nrf2/Bach1 modulator with a novel mechanism for sickle cell disease, distinct from gene therapies and hydroxyurea
  • FDA Orphan Drug Designation provides 7-year market exclusivity if approved, plus tax credits and fee waivers, and signals regulatory interest
  • Preclinical data showed fetal hemoglobin induction comparable to or exceeding hydroxyurea, the current standard of care
Bear case
  • HPPD is still preclinical with no IND filed and no human data; most preclinical drug candidates never reach the market
  • The company's primary focus and $77.2M cash runway are allocated to the cadisegliatin Phase 3 trial, not HPPD advancement
  • Sickle cell disease has multiple approved treatments including gene therapies (Casgevy, Lyfgenia) and hydroxyurea, creating a competitive landscape

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Oct 6, 2026cadisegliatinBreakthrough designation+2.2%−6.9%
May 13, 2026cadisegliatinBreakthrough designation+19.7%+14.0%